Comparative Pharmacology
Head-to-head clinical analysis: JELMYTO versus MITHRACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JELMYTO versus MITHRACIN.
JELMYTO vs MITHRACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JELMYTO (mitomycin) is a mitomycin-containing gel that induces apoptosis by cross-linking DNA, inhibiting DNA synthesis, and producing reactive oxygen species, with additional local tumoricidal effects via thermal ablation of the mitomycin-containing hydrogel.
Binds to DNA and inhibits RNA synthesis; also inhibits osteoclast activity by blocking mRNA transcription.
Instill 4 mg (1 vial) into the renal pelvis via ureteral catheter or nephrostomy tube, once weekly for 6 weeks, followed by monthly maintenance for up to 11 months. Administer 2 mL of sterile water for irrigation through the catheter to ensure delivery; clamp for 1 hour.
25 mcg/kg intravenously over 4-6 hours daily for 8-10 days; for hypercalcemia, 25 mcg/kg intravenously once. Maximum cumulative dose due to toxicity: 10-30 mcg/kg per course.
None Documented
None Documented
Following intravesical administration, systemic absorption is negligible, so terminal half-life is not clinically relevant. Mitomycin given intravenously has a terminal half-life of 23-78 minutes (triphasic); this is not applicable for intravesical JELMYTO.
Terminal half-life: 18-36 hours (mean 27 hours); clinically, this supports intermittent dosing every 1-2 weeks to avoid accumulation.
JELMYTO (mitomycin) is not absorbed systemically after intravesical administration; urinary excretion is the primary route of elimination of the administered dose. Less than 1% of the dose is absorbed and undergoes hepatic metabolism and biliary/fecal excretion.
Renal: ~90% unchanged within 24 hours; biliary/fecal: <10% as metabolites.
Category C
Category C
Antineoplastic Antibiotic
Antineoplastic Antibiotic